RxDoctor Payments Data

Ravi Choxi

Cardiovascular Disease · Burlington, MANPI 1184112492

Payments from drug & device makers

$39,305in general payments, 2019–2025

Across 231 payments — averaging $170.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$20K
  • Medtronic$9K
  • Boston Scientific$6K
  • Biosense Webster, Inc.$2K
  • Biotronik Inc.$1K
  • E.r. Squibb & Sons, L.L.C.$315
  • plus $598 from 10 others

What the payments were for

  • Grants$19,43849%
  • Travel & lodging$11,25129%
  • Food & beverage$7,74920%
  • Education$8672%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,305 in reported general payments places this provider in the 80th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$2,482
Medicare patients
21
Services billed
21

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban48$42,098
Metoprolol Succinate27$518
Ezetimibe15$514
Atorvastatin Calcium23$246
Amlodipine Besylate20$197
Metoprolol Tartrate22$142

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$135$42,09848 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in Burlington

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →